University of Groningen Physiology and Biochemistry of Primary Alcohol
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
(12) Patent Application Publication (10) Pub. No.: US 2013/0089535 A1 Yamashiro Et Al
US 2013 0089535A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0089535 A1 Yamashiro et al. (43) Pub. Date: Apr. 11, 2013 (54) AGENT FOR REDUCING ACETALDEHYDE Publication Classification NORAL CAVITY (51) Int. Cl. (75) Inventors: Kan Yamashiro, Kakamigahara-shi (JP); A68/66 (2006.01) Takahumi Koyama, Kakamigahara-shi A638/51 (2006.01) (JP) A61O 11/00 (2006.01) A638/44 (2006.01) Assignee: AMANOENZYME INC., Nagoya-shi (52) U.S. Cl. (73) CPC. A61K 8/66 (2013.01); A61K 38/44 (2013.01); (JP) A61 K38/51 (2013.01); A61O II/00 (2013.01) (21) Appl. No.: 13/703,451 USPC .......... 424/94.4; 424/94.5; 435/191: 435/232 (22) PCT Fled: Jun. 7, 2011 (57) ABSTRACT Disclosed herein is a novel enzymatic agent effective in (86) PCT NO.: PCT/UP2011/062991 reducing acetaldehyde in the oral cavity. It has been found S371 (c)(1), that an aldehyde dehydrogenase derived from a microorgan (2), (4) Date: Dec. 11, 2012 ism belonging to the genus Saccharomyces and a threonine aldolase derived from Escherichia coli are effective in reduc (30) Foreign Application Priority Data ing low concentrations of acetaldehyde. Therefore, an agent for reducing acetaldehyde in the oral cavity is provided, Jun. 19, 2010 (JP) ................................. 2010-140O26 which contains these enzymes as active ingredients. Patent Application Publication Apr. 11, 2013 Sheet 1 of 2 US 2013/0089535 A1 FIG 1) 10.5 1 0 9.9.5 8. 5 CONTROL TA AD (BSA) ENZYME Patent Application Publication Apr. 11, 2013 Sheet 2 of 2 US 2013/0089535 A1 FIG 2) 110 the CONTROL (BSA) 100 354. -
Adaptive Laboratory Evolution Enhances Methanol Tolerance and Conversion in Engineered Corynebacterium Glutamicum
ARTICLE https://doi.org/10.1038/s42003-020-0954-9 OPEN Adaptive laboratory evolution enhances methanol tolerance and conversion in engineered Corynebacterium glutamicum Yu Wang 1, Liwen Fan1,2, Philibert Tuyishime1, Jiao Liu1, Kun Zhang1,3, Ning Gao1,3, Zhihui Zhang1,3, ✉ ✉ 1234567890():,; Xiaomeng Ni1, Jinhui Feng1, Qianqian Yuan1, Hongwu Ma1, Ping Zheng1,2,3 , Jibin Sun1,3 & Yanhe Ma1 Synthetic methylotrophy has recently been intensively studied to achieve methanol-based biomanufacturing of fuels and chemicals. However, attempts to engineer platform micro- organisms to utilize methanol mainly focus on enzyme and pathway engineering. Herein, we enhanced methanol bioconversion of synthetic methylotrophs by improving cellular tolerance to methanol. A previously engineered methanol-dependent Corynebacterium glutamicum is subjected to adaptive laboratory evolution with elevated methanol content. Unexpectedly, the evolved strain not only tolerates higher concentrations of methanol but also shows improved growth and methanol utilization. Transcriptome analysis suggests increased methanol con- centrations rebalance methylotrophic metabolism by down-regulating glycolysis and up- regulating amino acid biosynthesis, oxidative phosphorylation, ribosome biosynthesis, and parts of TCA cycle. Mutations in the O-acetyl-L-homoserine sulfhydrylase Cgl0653 catalyzing formation of L-methionine analog from methanol and methanol-induced membrane-bound transporter Cgl0833 are proven crucial for methanol tolerance. This study demonstrates the importance of -
(12) Patent Application Publication (10) Pub. No.: US 2012/0028333 A1 Piatesi Et Al
US 20120028333A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0028333 A1 Piatesi et al. (43) Pub. Date: Feb. 2, 2012 (54) USE OF ENZYMES TO REDUCE ALDEHYDES (30) Foreign Application Priority Data FROMALDEHYDE-CONTAINING PRODUCTS Apr. 7, 2009 (EP) .................................. O9157522.5 Publication Classification (76) Inventors: Andrea Piatesi, Mannheim (DE); (51) Int. Cl. Tilo Habicher, Speyer (DE); CI2N 9/02 (2006.01) Michael Bischel, Worms (DE); CI2N I/00 (2006.01) Li-Wen Wang, Mannheim (DE): CI2N 15/63 (2006.01) Jirgen Reichert, Limburgerhof A62D 3/02 (2007.01) (DE); Rainer Packe-Wirth, C7H 2L/04 (2006.01) Trostberg (DE); Kai-Uwe (52) U.S. Cl. ... 435/189: 435/262:536/23.2:435/320.1; Baldenius, Heidelberg (DE); Erich 435/243 Kromm, Weisenheim am Sand (57) ABSTRACT (DE); Stefan Häfner, Speyer (DE); Carsten Schwalb. Mannheim (DE); The invention relates to the use of an enzyme preparation Hans Wolfgang Höffken, which catalyzes the degradation of formaldehyde for reduc Ludwigshafen (DE) ing the formaldehyde content in a formaldehyde-containing formulation. In a preferred embodiment, the enzyme prepa ration contains a formaldehyde dismutase from a Pseudomo (21) Appl. No.: 13/262,662 nas putida Strain. Further, the invention refers to a process for reducing the formaldehyde content in cross-linking agents for textile finishing or in polymer dispersions used, e.g. in con (22) PCT Filed: Mar. 31, 2010 struction chemistry. Further the invention relates to the use of an enzyme preparation which catalyzes the degradation of (86). PCT No.: PCT/EP1OAS4284 aldehydes for reducing the formaldehyde content in an alde hyde-containing formulation. -
2021 Code Changes Reference Guide
Boston University Medical Group 2021 CPT Code Changes Reference Guide Page 1 of 51 Background Current Procedural Terminology (CPT) was created by the American Medical Association (AMA) in 1966. It is designed to be a means of effective and dependable communication among physicians, patients, and third-party payers. CPT provides a uniform coding scheme that accurately describes medical, surgical, and diagnostic services. CPT is used for public and private reimbursement systems; development of guidelines for medical care review; as a basis for local, regional, and national utilization comparisons; and medical education and research. CPT Category I codes describe procedures and services that are consistent with contemporary medical practice. Category I codes are five-digit numeric codes. CPT Category II codes facilitate data collection for certain services and test results that contribute to positive health outcomes and quality patient care. These codes are optional and used for performance management. They are alphanumeric five-digit codes with the alpha character F in the last position. CPT Category III codes represent emerging technologies. They are alphanumeric five-digit codes with the alpha character T in the last position. The CPT Editorial Panel, appointed by the AMA Board of Trustees, is responsible for maintaining and updating the CPT code set. Purpose The AMA makes annual updates to the CPT code set, effective January 1. These updates include deleted codes, revised codes, and new codes. It’s important for providers to understand the code changes and the impact those changes will have to systems, workflow, reimbursement, and RVUs. This document is meant to assist you with this by providing a summary of the changes; a detailed breakdown of this year’s CPT changes by specialty, and HCPCS Updates for your reference. -
Enzymatic Conversion of CO2 to Methanol
Verónica Catarina Ferreira Amado Licenciada em Bioquímica “One-pot” enzymatic conversion of CO2 to methanol Dissertação para obtenção do Grau de Mestre em Biotecnologia Orientador: Susana Barreiros, Professora Associada com Agregação Universidade Nova de Lisboa Co-orientador: Alexandre Paiva, Investigador Doutorado Universidade Nova de Lisboa Júri: Presidente: Prof. Doutor Carlos Alberto Gomes Salgueiro Arguente: Doutora Ana Sofia Diogo Ferreira Vogal: Prof. Doutora Susana Filipe Barreiros Setembro de 2013 i ii “One-pot” enzymatic conversion of CO2 to methanol Copyright Verónica Catarina Ferreira Amado, FCT/UNL, UNL A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com objetivos educativos ou de investigação, não comerciais, desde que seja dado crédito ao autor e editor. iii iv Ao meu irmão Rafael v AGRADECIMENTOS Gostaria de agradecer a todos aqueles que me apoiaram nesta jornada e que, de algum modo contribuíram para a realização desta tese. Quero expressar a mais sincera gratidão aos meus orientadores. Em primeiro lugar à minha orientadora Prof. Doutora Susana Barreiros por todo o interesse e entusiasmo que demonstrou no meu trabalho, por todas as críticas científicas que tanto o enriqueceram, e por estar sempre disponível para discutir o mesmo. Gostaria de agradecer também ao meu co-orientador o Doutor Alexandre Paiva pela paciência, concelhos dados, discussão de ideias e alternativas, pelo espírito crítico sempre incisivo em pontos fulcrais e também pelos momentos de descontracção. -
Enzyme Immobilization for Use in Biofuel Cells and Sensors
(19) & (11) EP 2 343 766 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 13.07.2011 Bulletin 2011/28 H01M 8/16 (2006.01) C12Q 1/00 (2006.01) (21) Application number: 10179649.8 (22) Date of filing: 21.11.2003 (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • Minteer, Shelly, D. HU IE IT LI LU MC NL PT RO SE SI SK TR Pacific, MO 63069 (US) Designated Extension States: • Akers, Niki, L. AL LT LV MK St Louis, MO 63129 (US) • Moore, Christine, M. (30) Priority: 27.11.2002 US 429829 P St Louis, MO 63125 (US) 10.07.2003 US 486076 P 11.07.2003 US 617452 (74) Representative: Smaggasgale, Gillian Helen W.P. Thompson & Co (62) Document number(s) of the earlier application(s) in 55 Drury Lane accordance with Art. 76 EPC: London WC2B 5SQ (GB) 03812443.4 / 1 565 957 Remarks: (71) Applicant: ST. LOUIS UNIVERSITY This application was filed on 24-09-2010 as a St. Louis, MO 63110-0250 (US) divisional application to the application mentioned under INID code 62. (54) Enzyme immobilization for use in biofuel cells and sensors (57) Disclosed are bioanodes comprising a quater- cleotide. The ion conducting polymer membrane lies jux- nary ammonium treated Nation(R) polymer membrane taposed to a polymethylene green redox polymer mem- and a dehydrogenase incorporated within the treated Na- brane, which serves to electro-oxidize the reduced ade- tion(R) polymer. The dehydrogenase catalyzes the oxi- nine dinucleotide. -
Properties of Formaldehyde Dismutation Catalyzing Enzymeof
Agric. Biol. Chem., 48 (8), 2017-2023, 1984 2017 Properties of Formaldehyde Dismutation Catalyzing Enzymeof Pseudomonas putida F61 Nobuo Kato, Hisataka Kobayashi, Masayuki Shimao and Chikahiro Sakazawa Department of Environmental Chemistry and Technology, Tottori University, Tottori 680, Japan Received January 9, 1984 Twoforms of formaldehyde dismutase distinguishable on disc-gel electrophoresis were isolated from the cell-free extract of Pseudomonasputida ¥61. The mobilities on SDS-gel electrophoresis and the NH2-terminal amino acids (arginine) of the two enzyme species were identical. The COOH- terminal amino acid sequence was found to be -Ser-Gly-Lys. The enzyme was inhibited by carbonyl, reducing and sulfhydryl reagents. The enzyme catalyzed the cross-dismutation reaction between formaldehyde and an aldehyde, such as propionaldehyde, acrolein, butyraldehyde, isobutyraldehyde and crotonaldehyde. The enzyme also catalyzed a coupled oxidoreduction between an alcohol and an aldehyde (RCH2OH+ R CHO^RCHO+R CH2OH) without addition of an electron acceptor. Aliphatic alcohols and aldehydes of C2 to C4 were utilized in this reaction. In the preceding study,1} we found an en- (E; formaldehyde dismutase, X; unknown zyme, which catalyzed dismutation of form- prosthetic group, and XH2; its reduced form.) aldehyde to form equimolar amounts of meth- Furthermore, we have found that the enzyme anol and formic acid, in Pseudomonas putida catalyzes a unique alcohol: aldehyde oxido- F61. The enzyme, given the trivial name of reduction reaction: formaldehyde dismutase, was purified and RCH2OH+R CHO >RCHO+R CH2OH partially characterized. On the other hand, mammalian alcohol dehydrogenase (EC In this work, we describe more detailed 1.1.1.1) was reported to catalyze formalde- properties of this enzyme and its substrate hyde dismutation on the addition of a cata- specificities in the cross-dismutation and al- lytic amount of NAD+or one of its deriva- cohol: aldehyde oxidoreduction reactions. -
Original Article Compensatory Upregulation of Aldo-Keto Reductase 1B10 to Protect Hepatocytes Against Oxidative Stress During Hepatocarcinogenesis
Am J Cancer Res 2019;9(12):2730-2748 www.ajcr.us /ISSN:2156-6976/ajcr0097527 Original Article Compensatory upregulation of aldo-keto reductase 1B10 to protect hepatocytes against oxidative stress during hepatocarcinogenesis Yongzhen Liu1, Jing Zhang1, Hui Liu1, Guiwen Guan1, Ting Zhang1, Leijie Wang1, Xuewei Qi1, Huiling Zheng1, Chia-Chen Chen1, Jia Liu1, Deliang Cao2, Fengmin Lu3, Xiangmei Chen1 1State Key Laboratory of Natural and Biomimetic Drugs, Department of Microbiology and Infectious Disease Center, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, P. R. China; 2Department of Medical Microbiology, Immunology and Cell Biology, Simmons Cancer Institute at Southern Illinois University School of Medicine, 913 N, Rutledge Street, Springfield, IL 62794, USA; 3Peking University People’s Hospital, Peking University Hepatology Institute, Beijing 100044, P. R. China Received May 26, 2019; Accepted November 15, 2019; Epub December 1, 2019; Published December 15, 2019 Abstract: Aldo-keto reductase 1B10 (AKR1B10), a member of aldo-keto reductase superfamily, contributes to detox- ification of xenobiotics and metabolization of physiological substrates. Although increased expression of AKR1B10 was found in hepatocellular carcinoma (HCC), the role of AKR1B10 in the development of HCC remains unclear. This study aims to illustrate the role of AKR1B10 in hepatocarcinogenesis based on its intrinsic oxidoreduction abilities. HCC cell lines with AKR1B10 overexpression or knockdown were treated with doxorubicin or hydrogen peroxide to determinate the influence of aberrant AKR1B10 expression on cells’ response to oxidative stress. Using Akr1b8 (the ortholog of human AKR1B10) knockout mice, diethylnitrosamine (DEN) induced liver injury, chronic inflammation and hepatocarcinogenesis were explored. Clinically, the pattern of serum AKR1B10 relevant to disease progres- sion was investigated in a patient cohort with chronic hepatitis B (n=30), liver cirrhosis (n=30) and HCC (n=40). -
OXPHOS Remodeling in High-Grade Prostate Cancer Involves Mtdna Mutations and Increased Succinate Oxidation
ARTICLE https://doi.org/10.1038/s41467-020-15237-5 OPEN OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation Bernd Schöpf 1, Hansi Weissensteiner 1, Georg Schäfer2, Federica Fazzini1, Pornpimol Charoentong3, Andreas Naschberger1, Bernhard Rupp1, Liane Fendt1, Valesca Bukur4, Irina Giese4, Patrick Sorn4, Ana Carolina Sant’Anna-Silva 5, Javier Iglesias-Gonzalez6, Ugur Sahin4, Florian Kronenberg 1, ✉ Erich Gnaiger 5,6 & Helmut Klocker 7 1234567890():,; Rewiring of energy metabolism and adaptation of mitochondria are considered to impact on prostate cancer development and progression. Here, we report on mitochondrial respiration, DNA mutations and gene expression in paired benign/malignant human prostate tissue samples. Results reveal reduced respiratory capacities with NADH-pathway substrates glu- tamate and malate in malignant tissue and a significant metabolic shift towards higher succinate oxidation, particularly in high-grade tumors. The load of potentially deleterious mitochondrial-DNA mutations is higher in tumors and associated with unfavorable risk factors. High levels of potentially deleterious mutations in mitochondrial Complex I-encoding genes are associated with a 70% reduction in NADH-pathway capacity and compensation by increased succinate-pathway capacity. Structural analyses of these mutations reveal amino acid alterations leading to potentially deleterious effects on Complex I, supporting a causal relationship. A metagene signature extracted from the transcriptome of tumor samples exhibiting a severe mitochondrial phenotype enables identification of tumors with shorter survival times. 1 Institute of Genetic Epidemiology, Department of Genetics and Pharmacology, Medical University Innsbruck, Schöpfstraße 41, A-6020 Innsbruck, Austria. 2 Institute of Pathology, Neuropathology and Molecular Pathology, Medical University Innsbruck, Müllerstraße 44, A-6020 Innsbruck, Austria. -
Polyol Pathway Links Glucose Metabolism to the Aggressiveness
Published OnlineFirst January 17, 2018; DOI: 10.1158/0008-5472.CAN-17-2834 Cancer Metabolism and Chemical Biology Research Polyol Pathway Links Glucose Metabolism to the Aggressiveness of Cancer Cells Annemarie Schwab1, Aarif Siddiqui1, Maria Eleni Vazakidou1, Francesca Napoli1, Martin Bottcher€ 2, Bianca Menchicchi3, Umar Raza4, Ozge€ Saatci4, Angela M. Krebs5, Fulvia Ferrazzi6, Ida Rapa7, Katja Dettmer-Wilde8, Maximilian J. Waldner3, Arif B. Ekici6, Suhail Ahmed Kabeer Rasheed9, Dimitrios Mougiakakos2, Peter J. Oefner8, Ozgur Sahin4, Marco Volante7, Florian R. Greten10, Thomas Brabletz5, and Paolo Ceppi1 Abstract Cancer cells alter their metabolism to support their malig- sequencing confirmed a profound alteration of EMT in PP- nant properties. In this study, we report that the glucose- deficient cells, revealing a strong repression of TGFb signature transforming polyol pathway (PP) gene aldo-keto-reductase- genes. Excess glucose was found to promote EMT through 1-member-B1 (AKR1B1) strongly correlates with epithelial-to- autocrine TGFb stimulation, while PP-deficient cells were mesenchymal transition (EMT). This association was con- refractory to glucose-induced EMT. These data show that PP firmed in samples from lung cancer patients and from an represents a molecular link between glucose metabolism, can- EMT-driven colon cancer mouse model with p53 deletion. In cer differentiation, and aggressiveness, and may serve as a novel vitro, mesenchymal-like cancer cells showed increased AKR1B1 therapeutic target. levels, and AKR1B1 knockdown was sufficient to revert EMT. An Significance: A glucose-transforming pathway in TGFb-driven equivalent level of EMT suppression was measured by targeting epithelial-to-mesenchymal transition provides novel mecha- the downstream enzyme sorbitol-dehydrogenase (SORD), fur- nistic insights into the metabolic control of cancer differenti- ther pointing at the involvement of the PP. -
C1-Pathways in Methyloversatilis Universalis FAM5: Genome Wide Gene Expression and Mutagenesis Studies
Microorganisms 2015, 3, 175-197; doi:10.3390/microorganisms3020175 OPEN ACCESS microorganisms ISSN 2076-2607 www.mdpi.com/journal/microorganisms Article C1-Pathways in Methyloversatilis universalis FAM5: Genome Wide Gene Expression and Mutagenesis Studies Nathan M. Good 1,†, Andrew Lamb 1,2,‡, David A. C. Beck 2,3, N. Cecilia Martinez-Gomez 2,† and Marina G. Kalyuzhnaya 1,4,* 1 Department of Microbiology, University of Washington, Seattle, WA 98195-1700, USA; E-Mails: [email protected] (N.M.G.); [email protected] (A.L.) 2 Department of Chemical Engineering, University of Washington, Seattle, WA 98195-7735, USA; E-Mails: [email protected] (D.A.C.B.); [email protected] (N.C.M.G.) 3 eScience Institute, University of Washington, Seattle, WA 98195-1570, USA 4 Biology Department, San Diego State University, North Life Science Room 401, San Diego, CA 92182-4614, USA † Current address: Department of Microbiology and Molecular Genetics, Michigan State University, 6198 Biomedical Physical Sciences. East Lansing, MI 48824, USA. ‡ Current address: College of Science, Northeastern University, 360 Huntington Avenue, Boston, MA 02115, USA. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-619-594-5626. Academic Editor: Ludmila Chistoserdova Received: 5 January 2015 / Accepted: 26 March 2015 / Published: 9 April 2015 Abstract: Methyloversatilis universalis FAM5 utilizes single carbon compounds such as methanol or methylamine as a sole source of carbon and energy. Expression profiling reveals distinct sets of genes altered during growth on methylamine vs methanol. As expected, all genes for the N-methylglutamate pathway were induced during growth on methylamine. -
Functional Investigation of Methanol Dehydrogenase-Like Protein Xoxf in Methylobacterium Extorquens AM1
Research Collection Doctoral Thesis Functional investigation of methanol dehydrogenase-like protein XoxF in Methylobacterium extorquens AM1 Author(s): Schmidt, Sabrina Publication Date: 2010 Permanent Link: https://doi.org/10.3929/ethz-a-006212345 Rights / License: In Copyright - Non-Commercial Use Permitted This page was generated automatically upon download from the ETH Zurich Research Collection. For more information please consult the Terms of use. ETH Library DISS. ETH NO. 19282 Functional investigation of methanol dehydrogenase-like protein XoxF in Methylobacterium extorquens AM1 A dissertation submitted to the ETH ZURICH for the degree of DOCTOR OF SCIENCES Presented by SABRINA SCHMIDT Diplom biologist, TU Braunschweig Born on May 23, 1982 Citizen of Germany Accepted on the recommendation of Prof. Dr. Julia Vorholt Prof. Dr. Hauke Hennecke 2010 2 | Microbiology ETH Zurich ABSTRACT ....................................................................................................................... 5 ZUSAMMENFASSUNG .................................................................................................. 7 CHAPTER 1: INTRODUCTION .................................................................................... 9 1.1 AEROBIC METHYLOTROPHIC BACTERIA .................................................................... 9 1.2 THE HABITAT OF AEROBIC METHYLOTROPHIC BACTERIA ......................................... 9 1.3 THE OXIDATION OF METHANOL TO FORMALDEHYDE IN METHYLOTROPHIC MICROORGANISMS..................................................................................................